News and Perspective

AD remains a significant global health challenge. Approvals of anti-amyloid antibodies by the FDA have reinforced confidence in the therapeutic potential of anti-amyloid therapies, which represent an advanced class of disease-modifying approaches. However, the relationship between amyloid clearance and meaningful clinical outcomes has been inconsistent across studies. In this context, a new secondary analysis of the phase 3 TRAILBLAZER-ALZ 2 trial provides additional evidence, showing that lower posttreatment amyloid levels are associated with slower clinical decline and favorable changes in AD-related biomarkers, thereby strengthening the correlation between amyloid clearance and meaningful patient outcomes.